Abstract Number: PB1359
Meeting: ISTH 2020 Congress
Theme: Platelet Disorders and von Willebrand Disease » Acquired Thrombocytopenias
Background: Drug-induced thrombocytopenia is a common side-effect. Up to 25% of thrombocytopenia in critically patients are drug-induced.
Aims: The aim of this case is to recall the potentiel adverse effects of drugs in elderly patients.
Methods: We report a Glibenclamide-induced thrombocytopenia in an elderly woman.
Results: A 75-year-old woman was admitted for headache. She had mellitus diabetes, high blood pressure and coronary insufficiency. She was treated with Glibenclamide, Metformine, Aspirin, Molsidomine and Captopril. Physical examination showed global cardiac failure. She had no features of bleeding. Laboratory tests showed thrombocytopenia with a thrombocyte count at 42000/mm3, hemoglobin levels of 14 g/dL and leucocytes at 7910/mm3. Renal and liver fonction were within normal range. Abdominal ultrasound was normal. Hepatitis B and C and human immunodeficiency virus serologies were negative. Glibenclamide was withdrawn. Three days after the withdrawal of Glibenclamide, platelets count increased with normal levels at 174000/mm3.
Conclusions: The etiological analysis of Glibenclamide-induced thrombocytopenia is not obvious. Different mechanisms were uncertain including auto-immune disease, bone marrow failure and impaired platelet production. Severe bleeding can occur. Therefore, platelet count should be monitored when patient are treated with Glibenclamide.
To cite this abstract in AMA style:
Cherif Y, Mrouki M, Derbel S, Ben Dahmen F, Abdallah M. Glibenclamide-Induced Thrombocytopenia: A Case Reort [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/glibenclamide-induced-thrombocytopenia-a-case-reort/. Accessed March 22, 2024.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/glibenclamide-induced-thrombocytopenia-a-case-reort/